AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11045249 — intervention group
Group type: EXPERIMENTAL
Intervention: OBF tonograph
Number of subjects: 102
Study 11045249 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 102
Study 11045249 — intervention group
Group type: COMPARATOR
Intervention: ECG pulse rate
Number of subjects: 102
Study 8853082 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-sufentanil
Number of subjects: 329
Study 8853082 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil-midazolam
Number of subjects: 329
Study 1381210 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg per day of medroxyprogesterone acetate (MPA)
Number of subjects: 21
Study 1381210 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy regimen (cisplatin, 5‐fluorouracil, methotrexate, bleomycin, vincristine)
Number of subjects: 21
Study 6361006 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam 30 mg
Number of subjects: 57
Study 6361006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 29225060 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior robot‐assisted radical prostatectomy
Number of subjects: 120
Study 29225060 — intervention group
Group type: COMPARATOR
Intervention: Anterior robot‐assisted radical prostatectomy
Number of subjects: 120
Study 26996107 — intervention group
Group type: EXPERIMENTAL
Intervention: 25000 IU/d retinyl palmitate (RP) for 6 months followed by 10000 IU/d RP for another 6 months
Number of subjects: 101
Study 25157723 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure combined with an individualized self-titration algorithm.
Number of subjects: 552
Study 25157723 — intervention group
Group type: COMPARATOR
Intervention: Usual care (routine blood pressure measurement and adjustment of medication if necessary).
Number of subjects: 552
Study 25157723 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring with self-titration of antihypertensive medication.
Number of subjects: 552
Study 25157723 — intervention group
Group type: COMPARATOR
Intervention: Usual care.
Number of subjects: 552
Study 23737510 — intervention group
Group type: EXPERIMENTAL
Intervention: mirtazapine 30 mg/day
Number of subjects: 40
Study 23737510 — intervention group
Group type: EXPERIMENTAL
Intervention: mirtazapine 15 mg/day
Number of subjects: 40
Study 23737510 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 20627502 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation with low-intensity exercise
Number of subjects: 32
Study 20627502 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 17492340 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (7 sessions of IPL, 9 sessions of low intense diode light, and biostimulation by drugs)
Number of subjects: 100
Study 17492340 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (7 sessions of IPL only)
Number of subjects: 100
Study 17213792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg per os on demand for 3 months (Group A)
Number of subjects: 20
Study 17213792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg per os on weekly fixed days (Monday‐Wednesday‐Friday) for 3 months (Group B)
Number of subjects: 20
Study 15108829 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-gauge Atraucan spinal needle (AT group)
Number of subjects: 215
Study 15108829 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge Whitacre spinal needle (WH group)
Number of subjects: 215
Study 15108829 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 215
Study 11422338 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB) 50-600 mg/day
Number of subjects: 19
Study 11422338 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB)
Number of subjects: 19
Study 9408785 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement condition (1 month's free membership)
Number of subjects: 300
Study 9408785 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition (letter by mail)
Number of subjects: 300
Study 9408785 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 300
Study 8508556 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (30 mg, alternate days)
Number of subjects: 24
Study 8508556 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg, daily)
Number of subjects: 24
Study 8508556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2950827 — intervention group
Group type: EXPERIMENTAL
Intervention: PDC-HDC diacetate (306.5 mg over five weeks, followed by 960 mg during maintenance)
Number of subjects: 44
Study 2950827 — intervention group
Group type: EXPERIMENTAL
Intervention: PDC-HDC diacetate
Number of subjects: 44
Study 2950827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 29653297 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial random noise stimulation (tRNS)
Number of subjects: 3
Study 29653297 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 3
Study 27076209 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (MEM) 20 mg p.o.
Number of subjects: 41
Study 27076209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 24722932 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (daily measuring of health parameters including ECG, blood pressure, weight, and self-assessment)
Number of subjects: 710
Study 24722932 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring training and support
Number of subjects: 710
Study 24722932 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring system
Number of subjects: 710
Study 23335153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1 (one visit)
Number of subjects: 298
Study 23335153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2 (two visits)
Number of subjects: 298
Study 23335153 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 298
Study 20361391 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity
Number of subjects: 390
Study 20361391 — intervention group
Group type: COMPARATOR
Intervention: Control group (A allele carriers)
Number of subjects: 390
Study 17950982 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose administration (25 g)
Number of subjects: 56
Study 17950982 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo drink
Number of subjects: 56
Study 16813972 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-protected TPN (LP)
Number of subjects: 37
Study 16813972 — intervention group
Group type: COMPARATOR
Intervention: Light-exposed TPN (LE)
Number of subjects: 37
Study 14710772 — intervention group
Group type: COMPARATOR
Intervention: Mechanical tooth cleaning only (Period A)
Number of subjects: 10
Study 14710772 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthrinse (Period B)
Number of subjects: 10
Study 14710772 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% chlorhexidine gel (Period C)
Number of subjects: 10
Study 14710772 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (both Periods B and C)
Number of subjects: 10
Study 10910607 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR and JE vaccines nonsimultaneously (Group A)
Number of subjects: 145
Study 10910607 — intervention group
Group type: COMPARATOR
Intervention: MMR and JE vaccines simultaneously (Group B)
Number of subjects: 145
Study 7478973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive one-year follow-up at a secondary prevention specialist clinic
Number of subjects: 99
Study 7478973 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up in the primary health care system
Number of subjects: 99
Study 1699597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornflakes (350 g/d, providing 10.33 g RS/d)
Number of subjects: 8
Study 1699597 — intervention group
Group type: COMPARATOR
Intervention: Rice Krispies (380 g/d, providing 0.86 g RS/d)
Number of subjects: 8
Study 1699597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornflakes
Number of subjects: 8
Study 7365045 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure only for 2 weeks
Number of subjects: 8
Study 7365045 — intervention group
Group type: COMPARATOR
Intervention: Response prevention only for 2 weeks
Number of subjects: 8
Study 7365045 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (exposure + response prevention) for 2 weeks after initial treatments
Number of subjects: 8
Study 7365045 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional 2 weeks of exposure
Number of subjects: 8
Study 7365045 — intervention group
Group type: COMPARATOR
Intervention: Additional 2 weeks of response prevention
Number of subjects: 8
Study 29212562 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)-OSU6162
Number of subjects: 62
Study 29212562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 27759458 — intervention group
Group type: EXPERIMENTAL
Intervention: Amberen dietary supplement
Number of subjects: 125
Study 24754555 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle of Life (COL) intervention
Number of subjects: 635
Study 24754555 — intervention group
Group type: COMPARATOR
Intervention: Control group (those who did not receive COL)
Number of subjects: 635
Study 22116416 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunt placed with proGAV(®) adjustable valve, immediately adjusted to function (Group A)
Number of subjects: 0
Study 22116416 — intervention group
Group type: COMPARATOR
Intervention: Shunt placed with proGAV(®) adjustable valve, adjusted to the highest setting for 3 months then adjusted to function (Group B)
Number of subjects: 0
Study 22116416 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunt placed with proGAV(®) adjustable valve (both groups)
Number of subjects: 0
Study 20392515 — intervention group
Group type: EXPERIMENTAL
Intervention: Three breathlessness management training sessions
Number of subjects: 22
Study 20392515 — intervention group
Group type: COMPARATOR
Intervention: Single breathlessness management training session
Number of subjects: 22
Study 18155581 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial matrix excision
Number of subjects: 105
Study 18155581 — intervention group
Group type: COMPARATOR
Intervention: Orthonyxia
Number of subjects: 105
Study 15964160 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE/MPA 5 mg
Number of subjects: 100
Study 15964160 — intervention group
Group type: COMPARATOR
Intervention: CEE/MPA 2.5 mg
Number of subjects: 100
Study 15964160 — intervention group
Group type: COMPARATOR
Intervention: Tibolone 2.5 mg
Number of subjects: 100
Study 12943974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrethroid-impregnated curtains
Number of subjects: 96
Study 12943974 — intervention group
Group type: COMPARATOR
Intervention: Non-impregnated curtains
Number of subjects: 96
Study 10687548 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic multisegmental surface
Number of subjects: 20
Study 10687548 — intervention group
Group type: COMPARATOR
Intervention: Static surface (gel pad)
Number of subjects: 20
Study 8681149 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-cc saline bolus
Number of subjects: 20
Study 8681149 — intervention group
Group type: COMPARATOR
Intervention: No saline bolus
Number of subjects: 20
Study 2028354 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic/anti-inflammatory combined medication (Myprodol; Rio Ethicals)
Number of subjects: 43
Study 2028354 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory medication (Voltaren; Geigy)
Number of subjects: 43
Study 2028354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 2028354 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 43
Study 7005415 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 55
Study 7005415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 6737407 — intervention group
Group type: EXPERIMENTAL
Intervention: Book-instructed
Number of subjects: 71
Study 6737407 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-instructed
Number of subjects: 71
Study 6737407 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-instructed
Number of subjects: 71
Study 31383825 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/day for 2 months)
Number of subjects: 66
Study 31383825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 29945272 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow repetition zone (NPR, n=20) with 12/10/8 repetitions
Number of subjects: 39
Study 29945272 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide repetition zone (WPR, n=19) with 15/10/5 repetitions
Number of subjects: 39
Study 26070923 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded expander and facial mask (FM)
Number of subjects: 50
Study 26070923 — intervention group
Group type: COMPARATOR
Intervention: Banded expander and facial mask (FM)
Number of subjects: 50
Study 25010364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound using speckle tracking
Number of subjects: 81
Study 25010364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound using M mode
Number of subjects: 81
Study 25010364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleural elastance (PEL)
Number of subjects: 81
Study 21638147 — intervention group
Group type: EXPERIMENTAL
Intervention: NBCA (Histoacryl, Braun, Germany)
Number of subjects: 83
Study 21638147 — intervention group
Group type: COMPARATOR
Intervention: NBCA‐MS (Glubran2, General Enterprise Marketing, Viareggio, Lucca, Italy)
Number of subjects: 83
Study 20113764 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation Meter (PALM)
Number of subjects: 30
Study 18554204 — intervention group
Group type: EXPERIMENTAL
Intervention: AFL ablation
Number of subjects: 137
Study 18554204 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (control)
Number of subjects: 137
Study 16154735 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular intermittent epidural boluses (5 mL every half hour)
Number of subjects: 60
Study 16154735 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion of levobupivacaine 0.1% with fentanyl 2 microg/mL at a rate of 10 mL/h
Number of subjects: 60
Study 12094341 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/cisplatin combination
Number of subjects: 0
Study 12094341 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 0
Study 10421644 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SMT) infusion (250 micrograms/h) for 5 days
Number of subjects: 100
Study 10421644 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin (SMT) infusion (250 micrograms/h) for 5 days + sclerotherapy
Number of subjects: 100
Study 7804963 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) chemotherapy
Number of subjects: 331
Study 2316838 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 98
Study 2316838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 7352851 — intervention group
Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl hydrochloride
Number of subjects: 21
Study 7352851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31852096 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride glucose (TyG) index
Number of subjects: 26093
Study 28893757 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine and usual care
Number of subjects: 0
Study 28893757 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study 27059729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily for 12 weeks
Number of subjects: 12
Study 27059729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 25538468 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish after scaling and root planing (SRP)
Number of subjects: 30
Study 25538468 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel after scaling and root planing (SRP)
Number of subjects: 30
Study 25538468 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 30
Study 22545741 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance training (enhanced through video format and guided experiential exercise)
Number of subjects: 100
Study 22545741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acceptance training)
Number of subjects: 100
Study 19393887 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mm microcoaxial cataract surgery system
Number of subjects: 78
Study 19393887 — intervention group
Group type: COMPARATOR
Intervention: 2.2 mm microcoaxial cataract surgery system
Number of subjects: 78
Study 17601461 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity FES-ET (1 hour a day for 15 to 20 consecutive workdays)
Number of subjects: 19
Study 17601461 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity FES-ET (15 minutes of sensory electric stimulation 4 days a week, 1 hour of FES-ET on the fifth day)
Number of subjects: 19
Study 17601461 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity FES-ET
Number of subjects: 19
Study 17601461 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity FES-ET
Number of subjects: 19
Study 15684796 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 474
Study 15684796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 474
Study 10928571 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 20
Study 10928571 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 20
Study 10928571 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 9107585 — intervention group
Group type: EXPERIMENTAL
Intervention: Browne Pneumatic Impactor (BPI)
Number of subjects: 9
Study 8450326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (0.15 mg/kg/hr by continuous infusion for up to 14 days)
Number of subjects: 906
Study 8450326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 906
Study 8450326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 906
Study 3828486 — intervention group
Group type: EXPERIMENTAL
Intervention: pH 2.3 solution of 0.5 mg triazolam
Number of subjects: 4
Study 3828486 — intervention group
Group type: EXPERIMENTAL
Intervention: pH 6.0 solution of 0.5 mg triazolam
Number of subjects: 4
Study 3828486 — intervention group
Group type: EXPERIMENTAL
Intervention: pH 6.0 solution of 0.5 mg triazolam during cimetidine treatment (1200 mg day-1)
Number of subjects: 4
Study 30957525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Therapy‐based integrated treatment/management program (active treatment condition)
Number of subjects: 27
Study 30957525 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 27
Study 27126198 — intervention group
Group type: EXPERIMENTAL
Intervention: 54 mg genistein daily for 1 year
Number of subjects: 120
Study 27126198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 25519790 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of antiretroviral therapy (ART) within 2 weeks
Number of subjects: 816
Study 25519790 — intervention group
Group type: COMPARATOR
Intervention: Deferred initiation of antiretroviral therapy (ART) starting a median of 1.3 years after enrollment
Number of subjects: 816
Study 25519790 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment group
Number of subjects: 816
Study 23423316 — intervention group
Group type: EXPERIMENTAL
Intervention: Early start OKC exercises (EOKC) starting at the fourth week postoperatively within a restricted ROM (45° to 90°)
Number of subjects: 49
Study 23423316 — intervention group
Group type: COMPARATOR
Intervention: Late start OKC exercises (LOKC) starting at the 12th week postoperatively within a restricted ROM (0° to 90°)
Number of subjects: 49
Study 23423316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EOKC and LOKC groups
Number of subjects: 49
Study 21515846 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril
Number of subjects: 3366
Study 21515846 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 3366
Study 21515846 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3366
Study 18320302 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger expression intervention (n=51)
Number of subjects: 102
Study 18320302 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-emotional writing, n=51)
Number of subjects: 102
Study 17059439 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 90
Study 17059439 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 90
Study 17059439 — intervention group
Group type: COMPARATOR
Intervention: Physical training
Number of subjects: 90
Study 12632024 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (280 mg)
Number of subjects: 120
Study 12632024 — intervention group
Group type: COMPARATOR
Intervention: Control (no aprotinin)
Number of subjects: 120
Study 10692268 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (mean dose, 9 mg/d)
Number of subjects: 24
Study 10692268 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (mean dose, 17 mg/d)
Number of subjects: 24
Study 9441387 — intervention group
Group type: EXPERIMENTAL
Intervention: Paedamin
Number of subjects: 20
Study 9441387 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaminolac
Number of subjects: 20
Study 8225688 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocloprost (200 micrograms) given twice daily for 8 days
Number of subjects: 8
Study 8225688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3949999 — intervention group
Group type: EXPERIMENTAL
Intervention: Judges with only the label 'clinical depression'
Number of subjects: 56